XORTX Therapeutics Receives Nasdaq Extension, Aims to Meet Bid Price Rule
ByAinvest
Tuesday, Oct 21, 2025 3:22 am ET2min read
XRTX--
The notification from Nasdaq does not currently impact XORTX's listing on the Nasdaq Capital Market. The company has until January 19, 2026, to regain compliance with the minimum bid price requirement. During this period, the shares will continue to trade on the Nasdaq Capital Market. If the bid price of the shares closes at or above $1.00 per share for a minimum of 10 consecutive business days before the deadline, Nasdaq will consider the deficiency closed [1].
XORTX is listed on the TSX Venture Exchange and the notification does not affect the company's compliance status with this listing. The company is actively evaluating options to resolve the deficiency and regain compliance with Nasdaq Rule 5550(a)(2).
XORTX Therapeutics has a robust pipeline of therapies focused on kidney diseases and other health issues related to uric acid metabolism. Its lead program, XRx-026, is for the treatment of gout, while XRx-008 targets autosomal dominant polycystic kidney disease (ADPKD) and XRx-101 is for acute kidney and other acute organ injury associated with respiratory virus infections. The company's recent acquisition of a renal anti-fibrotic therapeutic program, VB4-P5, from Australia's Vectus Biosystems, aims to treat kidney fibrosis, an area of significant unmet medical need [2].
Despite financial challenges, XORTX maintains strong financial strength with a low debt-to-equity ratio. The company must ensure its shares close at or above $1.00 for ten consecutive business days before the deadline to avoid delisting. The acquisition of VB4-P5, which was priced at $3 million in XORTX shares, indicates the company's commitment to addressing large unmet needs in the kidney disease market [2].
Investors should remain cautious, as the path from lab success to FDA approval remains uncertain and the stock remains highly volatile. The acquisition of VB4-P5 is a significant step forward, but it will require clinical trials and regulatory approvals before any potential FDA green light. The $3 million stock-based payment will also dilute shareholders, a common risk as the company raises funds for research and development [2].
XORTX's recent stock price surge, which saw shares jump as much as 40% intraday on October 17, 2025, highlights the potential for significant gains if the company's therapies succeed. However, the stock remains down ~25% year-to-date and ~55% over the past 12 months, indicating the high-risk, high-reward nature of the investment [2].
XORTX Therapeutics has received a 180-day extension from Nasdaq to meet the $1.00 minimum bid price requirement. The company focuses on developing therapies for kidney diseases and other health issues related to uric acid metabolism. Despite financial challenges, XORTX maintains strong financial strength with a low debt-to-equity ratio. The company must ensure its shares close at or above $1.00 for ten consecutive business days before the deadline to avoid delisting.
Calgary, Alberta, September 12, 2025 — XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, has received a 180-day extension from the Nasdaq Stock Market LLC Listing Qualifications Department to meet the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) [1]. The company's shares have been trading below the $1.00 minimum bid price for 30 consecutive business days, which is a requirement for listing on Nasdaq.The notification from Nasdaq does not currently impact XORTX's listing on the Nasdaq Capital Market. The company has until January 19, 2026, to regain compliance with the minimum bid price requirement. During this period, the shares will continue to trade on the Nasdaq Capital Market. If the bid price of the shares closes at or above $1.00 per share for a minimum of 10 consecutive business days before the deadline, Nasdaq will consider the deficiency closed [1].
XORTX is listed on the TSX Venture Exchange and the notification does not affect the company's compliance status with this listing. The company is actively evaluating options to resolve the deficiency and regain compliance with Nasdaq Rule 5550(a)(2).
XORTX Therapeutics has a robust pipeline of therapies focused on kidney diseases and other health issues related to uric acid metabolism. Its lead program, XRx-026, is for the treatment of gout, while XRx-008 targets autosomal dominant polycystic kidney disease (ADPKD) and XRx-101 is for acute kidney and other acute organ injury associated with respiratory virus infections. The company's recent acquisition of a renal anti-fibrotic therapeutic program, VB4-P5, from Australia's Vectus Biosystems, aims to treat kidney fibrosis, an area of significant unmet medical need [2].
Despite financial challenges, XORTX maintains strong financial strength with a low debt-to-equity ratio. The company must ensure its shares close at or above $1.00 for ten consecutive business days before the deadline to avoid delisting. The acquisition of VB4-P5, which was priced at $3 million in XORTX shares, indicates the company's commitment to addressing large unmet needs in the kidney disease market [2].
Investors should remain cautious, as the path from lab success to FDA approval remains uncertain and the stock remains highly volatile. The acquisition of VB4-P5 is a significant step forward, but it will require clinical trials and regulatory approvals before any potential FDA green light. The $3 million stock-based payment will also dilute shareholders, a common risk as the company raises funds for research and development [2].
XORTX's recent stock price surge, which saw shares jump as much as 40% intraday on October 17, 2025, highlights the potential for significant gains if the company's therapies succeed. However, the stock remains down ~25% year-to-date and ~55% over the past 12 months, indicating the high-risk, high-reward nature of the investment [2].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet